within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AE05_Levofloxacin;

model Levofloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.99,
    Cl = 2.3888888888888887e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.074,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.019166666666666665,
    Tlag = 10.799999999999999,
    Vdp = 0.047,
    k12 = 3.4722222222222224e-06,
    k21 = 3.4722222222222224e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Levofloxacin</td></tr><tr><td>ATC code:</td><td>S01AE05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>74</td><td>L</td></tr>
    <tr><td>clearance:</td><td>8.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Levofloxacin is a broad-spectrum fluoroquinolone antibiotic used for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. It is an approved medication and is widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Canouï, E, et al., &amp; Benaboud, S (2022). Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections. <i>The Journal of antimicrobial chemotherapy</i> 77(5) 1344–1352. DOI:<a href=\"https://doi.org/10.1093/jac/dkac031\">10.1093/jac/dkac031</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35178577/\">https://pubmed.ncbi.nlm.nih.gov/35178577</a></p></li><li><p>Boonpeng, A, et al., &amp; Samaeng, M (2021). Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. <i>Biopharmaceutics &amp; drug disposition</i> 42(7) 329–337. DOI:<a href=\"https://doi.org/10.1002/bdd.2294\">10.1002/bdd.2294</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34117648/\">https://pubmed.ncbi.nlm.nih.gov/34117648</a></p></li><li><p>Jaruratanasirikul, S, et al., &amp; Samaeng, M (2018). Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. <i>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</i> 99(8) 886–892. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29947489/\">https://pubmed.ncbi.nlm.nih.gov/29947489</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AE05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Levofloxacin;
